In a motion to dismiss the lawsuit last year, lawyers for Mochi Health called the complaint part of a nationwide campaign to bolster Lillys profits by dictating patient care through the elimination of compounded drugs as a treatment option for weight management. The lawsuit is ongoing
Beyond diabetes management, GLP-1 medications have shown significant success in addressing obesity and supporting healthy weight loss
This qualitative difference matters enormously for adherence
GLP-1 therapy touches multiple clinical systems at once: appetite regulation, insulin signaling, cardiovascular risk, hormonal balance, and lean tissue preservation
This can be a game changer for so many people
At present, Retatrutide cannot be prescribed privately or via the NHS in the UK